Melanoma
From the Journals
Checkmate 238: Nivolumab bests ipilimumab for resectable stage III or IV melanoma
The rates of relapse-free survival were 71% at 12 months for patients assigned to adjuvant nivolumab, compared with 61% for adjuvant ipilimumab....
Original Report
Bone remodeling associated with CTLA-4 inhibition: an unreported side effect
Case Reports
Intramedullary spinal cord and leptomeningeal metastases presenting as cauda equina syndrome in a patient with melanoma
From the Journals
Pembrolizumab, nivolumab linked to 3% rate of neurologic events
Ten of 347 patients (2.9%) receiving nivolumab or pembrolizumab developed subacute neurologic immune-related adverse events, typically...
From the Journals
Adverse effects of PD-1/PD-L1 inhibitors varied by tumor type in systematic review
Patients with melanoma who received PD-1/PD-L1 inhibitors were significantly more likely to develop colitis, diarrhea, pruritus, and rash,...
From the Journals
California study indicates increased melanoma incidence is real
The results of an analysis of new melanoma cases in California among non-Hispanic whites suggests that increases in melanoma worldwide are not due...
Clinical Review
Targeted Therapy and Immunotherapy in the Treatment of Metastatic Cutaneous Melanoma
Conference Coverage
VIDEO: Immune therapy effective, durable in treatment-naive melanoma brain metastases
CHICAGO – For patients with asymptomatic brain metastases from melanoma who had not had prior treatment, nivolumab combined with ipilimumab...
From the Journals
Immediate-completion lymph node dissection in metastatic melanoma
Is lymph node dissection a must in patients with melanoma and sentinel node metastases?
Feature
Skin cancer procedures up by 35% since 2012
American Society for Dermatologic Surgery cites increased public awareness of skin cancer.
Conference Coverage
TRK inhibitor shows ‘striking’ activity, durability across diverse adult and pediatric cancers
An analysis of three trials involving 55 patients with advanced cancer harboring TRK fusions who were treated with larotrectinib showed an overall...